Semaglutide 1 mg FlexTouch Pen

Price range: 470.00$ through 1,300.00$

Product Overview The Semaglutide 1 mg FlexTouch Pen is a once‑weekly injectable therapy indicated for chronic weight management in adults with a body‑mass index (BMI) ≥ 27 kg/m² who also have at least one weight‑related condition such as hypertension

Pack Size	Price	Quantity
1 Pen	470.00$
2 Pen/s	900.00$
3 Pen/s	1,300.00$

Estimated Delivery: Tue, Jun 23 – Thu, Jun 25

... people are viewing this right now

Guaranteed Safe Checkout

🔒 We Accept — Secure International Payment

Bank Transfer

Wire / SWIFT

Zelle

US bank transfer

Crypto

BTC / ETH / USDT

Venmo

US payment app

After placing your order, you will receive full payment details by email. Your order is dispatched within 24 hours of payment confirmation. You can also order directly via WhatsApp for the fastest service.

🚚 Worldwide Shipping — Fully Tracked & Insured

United States

Standard tracked delivery

7–14 Business Days

United Kingdom

Standard tracked delivery

5–10 Business Days

Australia

Standard tracked delivery

10–18 Business Days

Rest of World

50+ countries available

10–20 Business Days

All orders are shipped in plain, discreet packaging with no pharmacy or medicine reference outside. Tracking number is sent by email after dispatch. Shipped from Mumbai, India.

Description

Product Overview

The Semaglutide 1 mg FlexTouch Pen is a once‑weekly injectable therapy indicated for chronic weight management in adults with a body‑mass index (BMI) ≥ 27 kg/m² who also have at least one weight‑related condition such as hypertension, dyslipidemia, or type 2 diabetes. Manufactured by Novo Nordisk India, the device delivers a precise 1 mg dose of semaglutide using a pre‑filled, ready‑to‑use FlexTouch pen equipped with four disposable needles. The product comes in pack sizes of 1, 2, or 3 pens, allowing patients to choose a supply that matches their treatment plan.

What is Semaglutide 1 mg FlexTouch Pen?

Semaglutide belongs to the class of glucagon‑like peptide‑1 (GLP‑1) receptor agonists. It mimics the action of the endogenous hormone GLP‑1, which regulates appetite, gastric emptying, and glucose homeostasis. The FlexTouch pen delivers a fixed dose of 1 mg semaglutide subcutaneously, typically in the abdomen, thigh, or upper arm. The pen’s design allows for simple, painless administration without the need for dose‑drawing or reconstitution, making it suitable for patients who prefer a user‑friendly delivery system.

Uses and Benefits

When combined with a reduced‑calorie diet and increased physical activity, semaglutide therapy can lead to meaningful weight loss and long‑term weight maintenance. Clinical studies have demonstrated average weight reductions of 10‑15 % of baseline body weight after 68 weeks of treatment. In addition to weight loss, patients often experience improvements in cardiovascular risk factors such as systolic blood pressure, LDL‑cholesterol, and glycemic control. The flexible dosing schedule — once weekly — supports adherence, and the pen’s discreet design enables use in various settings, including at home or while traveling.

How It Works

Semaglutide binds to GLP‑1 receptors in the brain’s appetite‑control centers, enhancing feelings of satiety and reducing hunger signals. It also slows gastric emptying, which prolongs the feeling of fullness after meals. These dual mechanisms result in lower caloric intake and gradual weight loss. Unlike other GLP‑1 agonists, semaglutide is administered at a higher weekly dose (1 mg) that has been shown to achieve robust weight‑reduction effects. The medication is metabolized primarily through proteolytic degradation, with an elimination half‑life of approximately one week, allowing for weekly dosing.

Dosage Guidelines

Treatment should be initiated under the supervision of a qualified healthcare professional. Typically, therapy begins with a 0.25 mg weekly dose for four weeks, after which the dose is escalated to 0.5 mg weekly for four weeks, then to 1 mg weekly thereafter. Dose adjustments may be required based on individual tolerance, comorbidities, and concomitant medications. Patients must be instructed to inject the medication on the same day each week, at any time of day, with or without food. The injection site should be rotated to minimize local skin irritation. For detailed dosing algorithms and titration schedules, refer to the prescribing information provided by Novo Nordisk.

Side Effects

Most adverse events are mild to moderate and transient. The most commonly reported side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These symptoms typically diminish over the first few weeks as the body adapts to the medication. Less frequent but clinically important adverse events may include pancreatitis, gallbladder disease, and acute kidney injury. Patients should be advised to seek medical attention if they experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction such as rash, pruritus, or swelling of the face and throat.

Warnings and Precautions

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). It should not be used during pregnancy or breastfeeding unless the potential benefit justifies the potential risk. Patients with a history of pancreatitis, severe gastrointestinal disease, or renal impairment should be monitored closely. Caution is advised when co‑administering with other GLP‑1 receptor agonists, insulin, or medications that may affect gastric motility. For comprehensive safety information, consult the FDA‑approved prescribing label or reputable sources such as FDA.gov and MedlinePlus.

Frequently Asked Questions

What is the recommended starting dose?
The standard initiation protocol begins with 0.25 mg administered subcutaneously once weekly for four weeks, followed by dose escalation to 0.5 mg and then 1 mg weekly, provided the patient tolerates the medication.
Can the pen be reused?
Each FlexTouch pen is designed for single‑use only. After the 1 mg dose is delivered, the pen should be discarded safely, and a new pen should be used for the next dose.
Is semaglutide safe for patients with type 2 diabetes?
Yes. Semaglutide improves glycemic control and can be used in patients with type 2 diabetes who also meet weight‑management criteria. However, dose adjustments may be necessary when used in combination with insulin or sulfonylureas to reduce the risk of hypoglycemia.
How long does shipping take?
Orders placed within India are typically delivered within 6 to 15 business days, depending on the shipping method selected and the destination.
Are there any dietary restrictions while using this medication?
No specific dietary restrictions are required, but a reduced‑calorie, balanced diet combined with regular physical activity enhances weight‑loss outcomes. Patients should follow the nutrition and exercise guidance provided by their healthcare provider.